Total Funding
20
7
Total FundingSeed raised
Growth Score
-30 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
57323
Anavo Therapeutics provides therapeutic potential of human phosphatase biology.
Birgit Zech: Co-Founder, Chief Executive Officer- Edward Holson: Chief Scientific Officer and President USPast Role: Amathus Therapeutics, Co-Founder, President, and Chief Scientific Officer
About the Company
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo
is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications
